Australia · Delayed Price · Currency is AUD ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of AUD 50.47 billion. The enterprise value is 49.66 billion.
| Market Cap | 50.47B |
| Enterprise Value | 49.66B |
Important Dates
The last earnings date was Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | Feb 11, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.43% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 73.75% |
| Float | 144.77M |
Valuation Ratios
The trailing PE ratio is 22.66 and the forward PE ratio is 21.13.
| PE Ratio | 22.66 |
| Forward PE | 21.13 |
| PS Ratio | 6.24 |
| PB Ratio | 5.33 |
| P/TBV Ratio | 11.83 |
| P/FCF Ratio | 18.79 |
| P/OCF Ratio | 17.58 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.04, with an EV/FCF ratio of 18.49.
| EV / Earnings | 22.29 |
| EV / Sales | 6.53 |
| EV / EBITDA | 17.04 |
| EV / EBIT | 19.04 |
| EV / FCF | 18.49 |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.06 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 0.47 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 26.60%.
| Return on Equity (ROE) | 25.68% |
| Return on Assets (ROA) | 14.75% |
| Return on Invested Capital (ROIC) | 26.60% |
| Return on Capital Employed (ROCE) | 25.44% |
| Weighted Average Cost of Capital (WACC) | 8.85% |
| Revenue Per Employee | 763,477 |
| Profits Per Employee | 210,153 |
| Employee Count | 10,600 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, ResMed has paid 498.95 million in taxes.
| Income Tax | 498.95M |
| Effective Tax Rate | 18.30% |
Stock Price Statistics
The stock price has decreased by -9.00% in the last 52 weeks. The beta is 0.88, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -9.00% |
| 50-Day Moving Average | 37.36 |
| 200-Day Moving Average | 39.53 |
| Relative Strength Index (RSI) | 35.02 |
| Average Volume (20 Days) | 1,253,701 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.68 |
Income Statement
In the last 12 months, ResMed had revenue of AUD 8.09 billion and earned 2.23 billion in profits. Earnings per share was 15.16.
| Revenue | 8.09B |
| Gross Profit | 4.98B |
| Operating Income | 2.77B |
| Pretax Income | 2.73B |
| Net Income | 2.23B |
| EBITDA | 3.04B |
| EBIT | 2.77B |
| Earnings Per Share (EPS) | 15.16 |
Balance Sheet
The company has 2.12 billion in cash and 1.27 billion in debt, with a net cash position of 853.57 million.
| Cash & Cash Equivalents | 2.12B |
| Total Debt | 1.27B |
| Net Cash | 853.57M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.48B |
| Book Value Per Share | 65.06 |
| Working Capital | 3.85B |
Cash Flow
In the last 12 months, operating cash flow was 2.87 billion and capital expenditures -184.23 million, giving a free cash flow of 2.69 billion.
| Operating Cash Flow | 2.87B |
| Capital Expenditures | -184.23M |
| Free Cash Flow | 2.69B |
| FCF Per Share | n/a |
Margins
Gross margin is 61.47%, with operating and profit margins of 34.19% and 27.53%.
| Gross Margin | 61.47% |
| Operating Margin | 34.19% |
| Pretax Margin | 33.69% |
| Profit Margin | 27.53% |
| EBITDA Margin | 37.51% |
| EBIT Margin | 34.19% |
| FCF Margin | 33.19% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 1.03%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 1.03% |
| Dividend Growth (YoY) | 14.67% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 2.32% |
| Buyback Yield | 0.43% |
| Shareholder Yield | 1.40% |
| Earnings Yield | 4.41% |
| FCF Yield | 5.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 12, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Aug 12, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
ResMed has an Altman Z-Score of 12.89 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.89 |
| Piotroski F-Score | 6 |